{"id":"NCT02174848","sponsor":"ApoPharma","briefTitle":"Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration","officialTitle":"Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2018-03-16","completion":"2018-03-16","firstPosted":"2014-06-26","resultsPosted":"2019-07-17","lastUpdate":"2020-08-25"},"enrollment":68,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pantothenate Kinase-Associated Neurodegeneration"],"interventions":[{"type":"DRUG","name":"Deferiprone oral solution","otherNames":["DFP"]}],"arms":[{"label":"Deferiprone","type":"EXPERIMENTAL"}],"summary":"Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"18 months","effectByArm":[{"arm":"Placebo-DFP","deltaMin":22,"sd":null},{"arm":"DFP-DFP","deltaMin":42,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":4,"countries":["United States","Germany","Italy","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":68},"commonTop":["Dystonia","Pyrexia","Headache","Serum ferritin decreased","Condition aggravated"]}}